Amicus Therapeutics Intrinsic Value Calculator – AMICUS THERAPEUTICS Reports Third Quarter Earnings for 2023 on November 8

🌥️Earnings Overview

On November 8, 2023, AMICUS THERAPEUTICS ($NASDAQ:FOLD) announced its fiscal year 2023 quarterly earnings results ending on September 30, 2023. Total revenue was reported to be USD 103.5 million, a 26.7% increase from the same period of the previous year. Net income for the quarter was USD -21.6 million, compared to -33.3 million in the year prior.

Stock Price

On Wednesday, November 8th, AMICUS THERAPEUTICS released its earnings report for the third quarter of 2023. The stock opened at $11.4 and remained at that price for the day, closing at $11.4 as well. This is a decrease of 3.0% from the previous closing price of $11.7. The market has responded with a dip in the stock price, reflecting uncertainty about the company’s financial performance.

This is a positive sign that the company has increased their quarterly earnings and is doing well overall. These results suggest that despite the 3.0% dip in their stock price, AMICUS THERAPEUTICS’ financial performance is strong and should continue to improve in the future. Investors will want to keep an eye on the company’s future earnings releases to see if this trend continues. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Amicus Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Amicus Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Amicus Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Amicus Therapeutics are shown below. More…

Analysis – Amicus Therapeutics Intrinsic Value Calculator

At GoodWhale, we have analyzed AMICUS THERAPEUTICS‘s financials to get an insight into their intrinsic value. We have calculated that the intrinsic value of AMICUS THERAPEUTICS share is around $12.0 using our proprietary Valuation Line. More…

Peers

The company’s competitors include SpringWorks Therapeutics Inc, Synthetic Biologics Inc, and Tonix Pharmaceuticals Holding Corp.

– SpringWorks Therapeutics Inc ($NASDAQ:SWTX)

Springs Works Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of treatments for patients with psychiatric and neurological disorders. The company’s most advanced product candidate is brexanolone, which is in Phase III clinical trials for the treatment of postpartum depression. Springs Works has a market cap of $1.52 billion and a return on equity of -64.67%.

– Synthetic Biologics Inc ($NYSEAM:SYN)

The company’s market cap is 28.98M as of 2022 and its ROE is -26.13%. The company’s products include prescription and over-the-counter drugs, as well as medical devices and supplies. The company has operations in the United States, Europe, Asia, and Latin America. The company’s products are sold through a network of retail pharmacies, wholesalers, and distributors.

Summary

AMICUS THERAPEUTICS reported strong earnings for the third quarter of fiscal year 2023, with total revenue of USD 103.5 million representing a 26.7% year-over-year increase. Net income was USD -21.6 million, a significant improvement over the -33.3 million reported in the same period of the previous year. Despite this, the company’s stock price dropped the same day, indicating a grim outlook for the stock from investors. Nevertheless, it appears AMICUS THERAPEUTICS is financially healthy and growing, thus presenting an opportunity for investors to consider.